참고문헌
- Ali IU, Schriml LM, Dean M (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. JNCI J Natl Cancer Inst, 91, 1922-32. https://doi.org/10.1093/jnci/91.22.1922
- Ashton K, Proietto A, Otton G, et al (2009). Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG, 116, 1053-61. https://doi.org/10.1111/j.1471-0528.2009.02185.x
- Balik G, Kagitci M, Ustuner I, et al (2013). Which endometrial pathologies need intraoperative frozen sections? Asian Pac J Cancer Prev, 14, 6121-5. https://doi.org/10.7314/APJCP.2013.14.10.6121
- Bansal N, Yendluri V, Wenham RM (2009). The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control J Moffitt Cancer Cente, 16, 8. https://doi.org/10.1177/107327480901600102
- Chalhoub N, Baker SJ (2009). PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol, 4, 127. https://doi.org/10.1146/annurev.pathol.4.110807.092311
- Chow LM, Baker SJ (2006). PTEN function in normal and neoplastic growth. Cancer Lett, 241, 184-96. https://doi.org/10.1016/j.canlet.2005.11.042
- Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009). Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol, 114, 121-7. https://doi.org/10.1016/j.ygyno.2009.03.039
- Gadducci A, Cosio S, Genazzani AR (2011). Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematolv, 80, 181-92. https://doi.org/10.1016/j.critrevonc.2010.11.005
- Gericke A, Munson M, Ross AH (2006). Regulation of the PTEN phosphatase. Gene, 374, 1-9. https://doi.org/10.1016/j.gene.2006.02.024
- Hernandez E, Obermair A, Hoskins PJ, Magrina JF, Mclellan R (2010). Controversies in the management of endometrial cancer. Obstet Gynecol Int. [Epub ahead of print].
- Jiang X-F, Tang Q-L, Zou Y, et al (2014). Does HBV infection increase risk of endometrial carcinoma? Asian Pac J Cancer Prev, 15, 713-6. https://doi.org/10.7314/APJCP.2014.15.2.713
- Konopka B, Janiec-Jankowska A, Czapczak D, et al (2007). Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol, 133, 361-71. https://doi.org/10.1007/s00432-006-0179-4
- Lee J-O, Yang H, Georgescu M-M, et al (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell, 99, 323-34. https://doi.org/10.1016/S0092-8674(00)81663-3
- Liu FS (2007). Molecular carcinogenesis of endometrial cancer. Taiwanese J Obstet Gynecol, 46, 26-32. https://doi.org/10.1016/S1028-4559(08)60102-3
- Minaguchi T, Yoshikawa H, Oda K, et al (2001). PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clinical Cancer Res, 7, 2636-42.
- Myatt SS, Wang J, Monteiro LJ, et al (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res, 70, 67-377. https://doi.org/10.1158/1538-7445.AM10-67
- Okuda T, Sekizawa A, Purwosunu Y, et al (2010). Genetics of endometrial cancers. Obstet Gynecol Internl, 2010.
- Ortega-Molina A, Serrano M (2013). PTEN in cancer, metabolism, and aging. Trends Endocrinol Meta, 24, 184-9. https://doi.org/10.1016/j.tem.2012.11.002
- Prat J, Gallardo A, Cuatrecasas M, Catasus L (2007). Endometrial carcinoma: pathology and genetics. Pathol, 39, 72-87. https://doi.org/10.1080/00313020601136153
- Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997). PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 57, 4736-8.
- Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A (1998). PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res, 4, 3005-10.
- Seeber L, Zweemer RP, Verheijen RH, van Diest PJ (2010). Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Internl, 2010.
- Smuc T, Rupreht R, Sinkovec J, Adamski J, Rizner TL (2006). Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrinol, 248, 114-7. https://doi.org/10.1016/j.mce.2005.10.013
- Sun H, Enomoto T, Fujita M, et al (2001). Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol, 115, 32-8. https://doi.org/10.1309/7JX6-B9U9-3P0R-EQNY
- Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, et al (2010). Endometrial cancer in Thai women: clinicopathological presentation and survival. Asian Pac J Cancer Prev, 11, 1267-72.
- Tashiro H, Blazes MS, Wu R, et al (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57, 3935-40.
- Thanapprapasr D, Thanapprapasr K (2013). Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev, 14, 3419-23. https://doi.org/10.7314/APJCP.2013.14.6.3419
- Voss MA, Ganesan R, Ludeman L, et al (2012). Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol, 124, 15-20. https://doi.org/10.1016/j.ygyno.2011.07.030
- Wang H-L, Liu M-M, Ma X, et al (2014). Expression and effects of JMJD2A histone demethylase in endometrial carcinoma. Asian Pac J Cancer Prev, 15, 3051. https://doi.org/10.7314/APJCP.2014.15.7.3051
-
Zhao T, Lv J, Zhao J, Nzekebaloudou M (2009). Hypoxiainducible factor-
$1{\alpha}$ gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res, 28, 159. https://doi.org/10.1186/1756-9966-28-159 - Zhu X-L, Ai Z-H, Wang J, et al (2012). Weighted gene coexpression network analysis in identification of endometrial cancer prognosis markers. Asian Pac J Cancer Prev, 13, 4607-11. https://doi.org/10.7314/APJCP.2012.13.9.4607
피인용 문헌
- Vicenin-2 acts as a radiosensitizer of the non-small cell lung cancer by lowering Akt expression pp.09516433, 2018, https://doi.org/10.1002/biof.1472